<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874393</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0041</org_study_id>
    <secondary_id>U10HD021364</secondary_id>
    <secondary_id>U10HD027880</secondary_id>
    <secondary_id>U10HD034216</secondary_id>
    <secondary_id>U10HD036790</secondary_id>
    <secondary_id>U10HD040492</secondary_id>
    <secondary_id>U10HD053089</secondary_id>
    <secondary_id>U10HD053124</secondary_id>
    <secondary_id>UL1RR025744</secondary_id>
    <secondary_id>UL1RR025764</secondary_id>
    <secondary_id>UL1RR025777</secondary_id>
    <secondary_id>U10HD027904</secondary_id>
    <secondary_id>U10HD027853</secondary_id>
    <secondary_id>U10HD040689</secondary_id>
    <secondary_id>U10HD027851</secondary_id>
    <secondary_id>UL1RR025008</secondary_id>
    <secondary_id>U10HD021373</secondary_id>
    <secondary_id>U10HD027856</secondary_id>
    <secondary_id>U10HD053109</secondary_id>
    <secondary_id>UL1RR024979</secondary_id>
    <secondary_id>U10HD053119</secondary_id>
    <secondary_id>UL1RR025747</secondary_id>
    <secondary_id>U10HD021385</secondary_id>
    <secondary_id>U10HD027871</secondary_id>
    <secondary_id>UL1RR024139</secondary_id>
    <nct_id>NCT00874393</nct_id>
  </id_info>
  <brief_title>Early Blood Pressure Management in Extremely Premature Infants</brief_title>
  <acronym>ELGAN BP</acronym>
  <official_title>Early Blood Pressure Management in Extremely Preterm Infants Feasibility Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Neonatal Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Neonatal Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial tests the feasibility of enrolling 60 extremely preterm infants in a randomized,
      double-blinded study of blood pressure management within 12 months. Eligible infants will
      receive an infusion drug (dopamine or a dextrose placebo) and a syringe drug (hydrocortisone
      or a normal saline placebo).

      Enrolled infants will be randomized to receive one of the following drug pairs:

        -  dopamine and hydrocortisone

        -  dopamine and normal saline

        -  dextrose and hydrocortisone

        -  dextrose and normal saline.

      In addition to the intervention above, the NRN is conducting a 6-month time-limited
      prospective observational study of all infants born at an NRN center between 23 and 26 weeks
      gestational age. All clinical decisions made for these babies will be at the discretion of
      the attending neonatologist/infant care team according to standard practice at each
      institution. Data on blood pressure management in the first 24 postnatal hours collected for
      each infant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since most extremely preterm infants are critically ill in the immediate postnatal period,
      establishing &quot;normal&quot; blood pressure (BP) values is difficult. This lack of data makes
      deciding when to institute therapy for hypotension (low BP) challenging, leading to
      considerable variability in BP management in neonatal intensive care units (NICUs). Despite a
      lack of data on safety or efficacy, as many as 64% of extremely preterm infants receive
      inotropes (e.g., dopamine), and up to 12.4% of very low birthweight infants receive
      hydrocortisone for perceived hypotension. Since both untreated low BP and therapy provided
      for low BP may be harmful, the decision of whether to treat is an important issue. To date,
      no prospective randomized, controlled trial of BP management in this population has been
      performed.

      This trial tests the feasibility of enrolling up to 60 extremely preterm infants in a
      randomized, double-blinded study of blood pressure management within 12 months. It will
      enroll 60 infants between 23 0/7 and 26 6/7 weeks gestational age born at 6 participating
      NICHD Neonatal Research Network sites. Eligible infants will receive a study infusion drug
      (dopamine or a dextrose placebo) and a study syringe drug (hydrocortisone or a normal saline
      placebo). Infants will be randomized to receive one of the following drug pairs: (1) dopamine
      and hydrocortisone; (2) dopamine and a placebo (normal saline solution); (3) a placebo
      (dextrose) and hydrocortisone; or (4) placebo (dextrose) and placebo (normal saline). (NOTE:
      dopamine is normally mixed with dextrose and hydrocortisone is mixed with saline solution
      before being administered, which is why two different placebos are being used in this trial.)

      The information gathered will provide a framework for the design of a potential larger,
      multi-centered, randomized control trial.

      NOTE: The NICHD Neonatal Research Network has received a FDA exemption from the IND
      regulations for this trial.

      In addition to the interventional trial above, the NRN is conducting a 6-month time-limited
      prospective observational study of all infants born at an NRN center between 23 and 26 weeks
      gestational age. All clinical decisions made for these babies will be at the discretion of
      the attending neonatologist/infant care team according to standard practice at each
      institution. Data on blood pressure management in the first 24 postnatal hours collected for
      each infant.

      Based on slow rate of recruitment, a time-limited observational study of hypotension in ELBW
      infants has been added to the current study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enrollment and completion of 60 infants</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1 week and prior to hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antihypotensive therapy</measure>
    <time_frame>First 96 postnatal hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receipt and timing of medical and/or surgical therapy for a PDA</measure>
    <time_frame>To hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of open-label antihypotensive therapies (inotropes, corticosteroids, blood and plasma volume expanders) for persistently low BP with biochemical evidence of poor perfusion</measure>
    <time_frame>First 96 postnatal hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous gastrointestinal perforation</measure>
    <time_frame>First 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital complications (grade III or IV intraventricular hemorrhage, cystic periventricular leukomalacia, necrotizing enterocolitis requiring surgical intervention, retinopathy of prematurity requiring laser surgery, or bronchopulmonary dysplasia)</measure>
    <time_frame>To hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Infant, Newborn</condition>
  <condition>Infant, Low Birth Weight</condition>
  <condition>Infant, Small for Gestational Age</condition>
  <condition>Infant, Premature</condition>
  <condition>Hypotension</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Dopamine and hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dopamine AND hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dopamine and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dopamine AND normal saline placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dextrose (D5W) placebo AND hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dextrose (D5W) placebo AND normal saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dopamine</intervention_name>
    <description>Dopamine</description>
    <arm_group_label>Dopamine and hydrocortisone</arm_group_label>
    <arm_group_label>Dopamine and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone</description>
    <arm_group_label>Dopamine and hydrocortisone</arm_group_label>
    <arm_group_label>Placebo and hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infusion Placebo</intervention_name>
    <description>Dextrose (D5W)</description>
    <arm_group_label>Placebo and hydrocortisone</arm_group_label>
    <arm_group_label>Placebo and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syringe Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Dopamine and placebo</arm_group_label>
    <arm_group_label>Placebo and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inborn infants

          -  23 0/7 to 26 6/7 weeks estimated gestational age

          -  Umbilical arterial catheter in place at study entry

          -  &lt;= 24 hours of age

        Exclusion Criteria:

          -  Terminally ill infants

          -  Infants that have received (prior to enrollment): &gt;20 ml/kg in fluid boluses,
             indomethacin, or ibuprofen

          -  Infants with major congenital anomalies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beau J. Batton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University, Rainbow Babies and Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald N. Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krisa P. Van Meurs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waldemar A Carlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristi L. Watterberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger G. Faix, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhik Das, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward F. Bell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abbot R. Laptook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara J. Stoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brenda P. Poindexter, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Schibler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen A. Kennedy, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo J. Sanchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seetha Shankaran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard A. Ehrenkranz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan D. Franz III, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTI International</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University, Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://neonatal.rti.org/</url>
    <description>NICHD Neonatal Research Network</description>
  </link>
  <results_reference>
    <citation>Batton BJ, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, Faix RG, Laughon MM, Van Meurs KP, Carlo WA, Higgins RD, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Feasibility study of early blood pressure management in extremely preterm infants. J Pediatr. 2012 Jul;161(1):65-9.e1. doi: 10.1016/j.jpeds.2012.01.014. Epub 2012 Feb 14.</citation>
    <PMID>22336574</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NICHD Neonatal Research Network</keyword>
  <keyword>Very Low Birth Weight (VLBW)</keyword>
  <keyword>Extremely Low Birth Weight (ELBW)</keyword>
  <keyword>Prematurity</keyword>
  <keyword>Blood Pressure Management</keyword>
  <keyword>Dopamine</keyword>
  <keyword>Hydrocortisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

